Disappearance of Trisomy 8 after Alpha-2 Interferon in a Patient with Myelodysplastic Syndrome

Publisher Website
Google Scholar
Abstract
To the Editor: The myelodysplastic syndromes are a group of disorders with heterogeneous hematologic and cytogenetic features1 that show an increased probability of transformation to acute myeloid leukemia. There is no cytoreductive therapy that is generally effective in eradicating the malignant cell clone and inducing complete remission in a majority of patients with these syndromes. Since the inability of the hematopoietic cells to differentiate is a prominent feature in myelodysplastic syndromes, therapeutic approaches aim to induce differentiation of these cells in vivo. For instance, therapy with 13-cis-retinoic acid has produced variable and sometimes favorable results.2 3 4 In September 1985, . . .